Spectral Provides Update to Shareholders

TORONTO, ONTARIO--(Marketwired - Feb. 19, 2015) - Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, is pleased to provide the Company's shareholders with an updated investor presentation which can be downloaded from the Spectral website at www.spectraldx.com or by simply clicking on the link below:

http://www.spectraldx.com/assets/spectral-medical-ir-feb2015.pdf

Investment Highlights:

• Spectral benefits from first mover advantage by being the only active Phase III clinical trial in septic shock, a deadly condition with a mortality rate greater than 40 percent;
• Over 100K patients in Japan and Europe have been successfully treated with Spectral's safe and effective device;
• Spectral is targeting more than 175K patients annually with septic shock in North America, at an end-user target pricing in the US$20K to US$30K range with potential EBITDA in excess of 40 percent;
• The Company is well capitalized and funded to 2H2016 with $10M in cash as at December 31, 2014, and with access to additional capital if required;
• As previously disclosed, Spectral is on a clear path to commercialization as early as 1H2016 (pending FDA approval).

About Spectral Medical Inc.

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study for a medical device in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit www.spectraldx.com.

Forward-looking statements

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the commercialization of Spectral's septic shock treatment, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.